tradingkey.logo

Tandem Diabetes Care Inc

TNDM
View Detailed Chart
19.170USD
+0.230+1.21%
Close 02/06, 16:00ETQuotes delayed by 15 min
1.30BMarket Cap
LossP/E TTM

Tandem Diabetes Care Inc

19.170
+0.230+1.21%
Intraday
1m
30m
1h
D
W
M
D

Today

+1.21%

5 Days

-3.62%

1 Month

-18.56%

6 Months

+33.22%

Year to Date

-12.78%

1 Year

-47.82%

View Detailed Chart

Key Insights

Tandem Diabetes Care Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 71 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 24.59.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Tandem Diabetes Care Inc's Score

Industry at a Glance

Industry Ranking
71 / 205
Overall Ranking
198 / 4521
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Tandem Diabetes Care Inc Highlights

StrengthsRisks
Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 17.35% year-on-year.
Overvalued
The company’s latest PE is -6.33, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 79.20M shares, decreasing 22.45% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 347.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.67.

Analyst Rating

Based on 24 analysts
Buy
Current Rating
24.591
Target Price
+29.84%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Tandem Diabetes Care Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Tandem Diabetes Care Inc Info

Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors.
Ticker SymbolTNDM
CompanyTandem Diabetes Care Inc
CEOSheridan (John F)
Websitehttps://www.tandemdiabetes.com/
KeyAI